These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 18607552)
21. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716 [TBL] [Abstract][Full Text] [Related]
22. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. Ho GH; Calvano JE; Bisogna M; Abouezzi Z; Borgen PI; Cordón-Cardó C; van Zee KJ Breast Cancer Res Treat; 2001 Feb; 65(3):225-32. PubMed ID: 11336244 [TBL] [Abstract][Full Text] [Related]
23. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594 [TBL] [Abstract][Full Text] [Related]
24. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503 [TBL] [Abstract][Full Text] [Related]
25. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Carr-Wilkinson J; O'Toole K; Wood KM; Challen CC; Baker AG; Board JR; Evans L; Cole M; Cheung NK; Boos J; Köhler G; Leuschner I; Pearson AD; Lunec J; Tweddle DA Clin Cancer Res; 2010 Feb; 16(4):1108-18. PubMed ID: 20145180 [TBL] [Abstract][Full Text] [Related]
26. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Esteller M; Cordon-Cardo C; Corn PG; Meltzer SJ; Pohar KS; Watkins DN; Capella G; Peinado MA; Matias-Guiu X; Prat J; Baylin SB; Herman JG Cancer Res; 2001 Apr; 61(7):2816-21. PubMed ID: 11306450 [TBL] [Abstract][Full Text] [Related]
27. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population. Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606 [TBL] [Abstract][Full Text] [Related]
28. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596 [TBL] [Abstract][Full Text] [Related]
29. Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein. Lavorato-Rocha AM; de Melo Maia B; Rodrigues IS; Stiepcich MM; Baiocchi G; da Silva Cestari FM; Carvalho KC; Soares FA; Rocha RM Ann Surg Oncol; 2013 Jan; 20(1):31-9. PubMed ID: 22878614 [TBL] [Abstract][Full Text] [Related]
30. Identification of spliced variants of the proto-oncogene HDM2 in colorectal cancer. Yu Z; Zhang B; Cui B; Wang Y; Han P; Wang X Cancer; 2012 Feb; 118(4):1110-8. PubMed ID: 21761395 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Lee M; Sup Han W; Kyoung Kim O; Hee Sung S; Sun Cho M; Lee SN; Koo H Pathol Res Pract; 2006; 202(6):415-24. PubMed ID: 16675157 [TBL] [Abstract][Full Text] [Related]
32. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators. Schlott T; Scharf JG; Gorzel C; Middel P; Spring H Br J Cancer; 2002 Apr; 86(8):1290-6. PubMed ID: 11953887 [TBL] [Abstract][Full Text] [Related]
33. Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia. Isin M; Yenerel M; Aktan M; Buyru N; Dalay N DNA Cell Biol; 2012 May; 31(5):777-82. PubMed ID: 22047081 [TBL] [Abstract][Full Text] [Related]
34. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas. Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452 [TBL] [Abstract][Full Text] [Related]
35. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hashiguchi Y; Tsuda H; Yamamoto K; Inoue T; Ishiko O; Ogita S Hum Pathol; 2001 Sep; 32(9):988-96. PubMed ID: 11567230 [TBL] [Abstract][Full Text] [Related]
36. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551 [TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-encoded EBNA-5 forms trimolecular protein complexes with MDM2 and p53 and inhibits the transactivating function of p53. Kashuba E; Yurchenko M; Yenamandra SP; Snopok B; Szekely L; Bercovich B; Ciechanover A; Klein G Int J Cancer; 2011 Feb; 128(4):817-25. PubMed ID: 20473904 [TBL] [Abstract][Full Text] [Related]